Scholarlink

<p>Currently, there are no reliable diagnostic or prognostic biomarkers for bladder cancer (BCa). This study aimed to assess the diagnostic and prognostic potential of the SPRY domain-containing suppressor of cytokine signaling box protein 2 (SPSB2) in patients with BCa. SPSB2 was detected by western blotting in urine but not in serum from patients with BCa and was absent in urine and serum from healthy volunteers. Urine-based ELISA revealed significantly higher SPSB2 expression in patients with BCa than in patients with urinary stones and healthy volunteers (<i>P</i> &lt; 0.0001); specifically, muscle-invasive BCa had significantly higher SPSB2 expression than non-muscle-invasive BCa (<i>P</i> = 0.003). The areas under the receiver operating curves for urine SPSB2 in patients with BCa and muscle-invasive BCa were 0.78 and 0.87, respectively. Third, unadjusted univariate analyses consistently showed worse prognostic impact of the high expression levels of urine SPSB2 for cancer-specific survival and progression-free survival irrespective of pT-stage, with the interaction <i>P</i> values of 0.71 for cancer-specific survival and 0.60 for progression-free survival. Thus, urine SPSB2 may represent a novel biomarker for the detection of muscle-invasive BCa and estimation of the biological aggressiveness of BCa. Further studies are needed to confirm these findings and investigate the potential mechanism of SPSB2 in BCa.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnostic and prognostic value of urine SPRY domain-containing suppressor of cytokine signaling box protein 2 for bladder cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月23日

查看全文
  • Dai Koguchi,
  • Noriyuki Amano,
  • Yuriko Shimizu,
  • Shuhei Hirano,
  • Soichiro Shimura,
  • Masaomi Ikeda,
  • Hideyasu Tsumura,
  • Daisuke Ishii,
  • Yuichi Sato,
  • Kazumasa Matsumoto

摘要

Currently, there are no reliable diagnostic or prognostic biomarkers for bladder cancer (BCa). This study aimed to assess the diagnostic and prognostic potential of the SPRY domain-containing suppressor of cytokine signaling box protein 2 (SPSB2) in patients with BCa. SPSB2 was detected by western blotting in urine but not in serum from patients with BCa and was absent in urine and serum from healthy volunteers. Urine-based ELISA revealed significantly higher SPSB2 expression in patients with BCa than in patients with urinary stones and healthy volunteers (P < 0.0001); specifically, muscle-invasive BCa had significantly higher SPSB2 expression than non-muscle-invasive BCa (P = 0.003). The areas under the receiver operating curves for urine SPSB2 in patients with BCa and muscle-invasive BCa were 0.78 and 0.87, respectively. Third, unadjusted univariate analyses consistently showed worse prognostic impact of the high expression levels of urine SPSB2 for cancer-specific survival and progression-free survival irrespective of pT-stage, with the interaction P values of 0.71 for cancer-specific survival and 0.60 for progression-free survival. Thus, urine SPSB2 may represent a novel biomarker for the detection of muscle-invasive BCa and estimation of the biological aggressiveness of BCa. Further studies are needed to confirm these findings and investigate the potential mechanism of SPSB2 in BCa.